Hillenbrand: Portfolio Transformation, Discounted Valuation, And Cyclical Recovery Set To Drive Upside

Hillenbrand (HI) has been upgraded to a Buy rating, anticipating a revenue rebound and margin expansion despite a recent pro forma 10% YoY revenue decline in Q3 2025. This positive outlook is driven by building order momentum in its Advanced Process Solutions (APS) and Molding Technology Solutions (MTS) segments, alongside a strategic portfolio shift towards higher-margin Food, Health, and Nutrition markets, which now comprise over 25% of total revenue following the exit from deathcare. With potential tailwinds from interest rate cuts, continued cost synergies, and a current valuation at a discount to historical forward P/E, the stock offers significant re-rating potential and a 3.5% dividend yield.

Analysis

Hillenbrand (HI) is presented as a compelling cyclical recovery play, supported by a strategic portfolio transformation despite near-term financial weakness. The company's Q3 2025 revenue declined 10% on a pro forma basis, with adjusted EBITDA margins contracting 360 basis points to 14.1% due to lower volumes and fixed cost absorption pressures in its core Advanced Process Solutions (APS) segment. However, forward-looking indicators are turning positive, with management citing a post-quarter pickup in order activity and a 7% pro forma backlog increase in the short-cycle Molding Technology Solutions (MTS) segment. A significant strategic shift is underway, with the higher-margin Food, Health & Nutrition (FHN) business growing to over 25% of total revenue from just 3% in 2022, driven by acquisitions that have already yielded $30 million in cost synergies ahead of schedule. The divestiture of the declining deathcare business and the MIME unit further cleans the portfolio. Valuation appears attractive, with the stock trading at 11.1x FY26 EPS, a discount to its five-year average of approximately 12.0x, even as the business is positioned at a cyclical low. A key headwind is the elevated pro forma net leverage of 3.7x, which is above the company's target range, but is being addressed by a pause in M&A activity. The 3.5% dividend yield provides a source of return while awaiting the fundamental turnaround.

Key Decisions for Investors

• Given the stock trades at a discount to its historical P/E multiple while fundamentals appear to be at a cyclical trough, investors may find the current valuation an attractive entry point ahead of an anticipated re-rating driven by revenue recovery and margin expansion.
• Investors should closely monitor the company's deleveraging progress, as the pro forma net leverage of 3.7x remains a key risk and a primary factor suppressing the valuation; a clear path toward the target range of 1.7x-2.7x could serve as a major catalyst.
• The thesis is sensitive to macro conditions, so it is crucial to watch for sustained improvement in order activity in the APS segment and any shifts in the outlook for interest rates and trade tariffs, which could accelerate or delay the recovery.
• The 3.5% dividend yield offers downside support and a tangible return, making the stock a consideration for investors with a medium-term horizon who are being paid to wait for the strategic and cyclical improvements to manifest in financial results.